TScan Therapeutics Reports Q3 Results: Revenue Beats Estimates Amid Strategic Shift
TScan Therapeutics (TCRX) reported third-quarter financial results characterized by a revenue beat but an earnings miss. The company posted GAAP earnings per share (EPS) of -$0.25, missing analyst expectations by $0.06. Despite this, quarterly revenue reached $0.59 million, exceeding estimates by $0.12 million, although this represents a significant 76.5% year-over-year decline. In a major strategic pivot, the company announced it is refocusing its efforts on in vivo cell therapy for solid tumors. As part of this realignment, TScan Therapeutics has decided to pause its Phase III study for hematologic (heme) indications. This shift marks a significant change in the company's clinical development roadmap and resource allocation.
Tickers: $TCRX
Topics: clinical trial pause earnings miss revenue beat strategic refocus
Read the full article at Seeking Alpha
Part of the story Valens Semiconductor Reports Q3 Revenue Beat and Strategic Shift Toward Mainstream Markets (3 articles)